Takeda Pharmaceutical Company Limited
TKPHF
$28.63
-$1.45-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.34% | 9.58% | 0.48% | -2.06% | -3.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.34% | 9.58% | 0.48% | -2.06% | -3.21% |
| Cost of Revenue | 6.32% | 11.54% | 6.11% | 15.10% | 7.89% |
| Gross Profit | -3.80% | 8.62% | -1.98% | -9.90% | -8.11% |
| SG&A Expenses | -2.10% | 3.08% | -4.17% | -0.21% | -2.58% |
| Depreciation & Amortization | -2.93% | 3.31% | -0.91% | 1.20% | -5.74% |
| Other Operating Expenses | 93.76% | -229.67% | 64.03% | 91.21% | 69.84% |
| Total Operating Expenses | 5.79% | -3.99% | 1.37% | 8.77% | 4.74% |
| Operating Income | -91.63% | 141.82% | -4.00% | -66.66% | -54.54% |
| Income Before Tax | -58.28% | 220.88% | -10.92% | -188.39% | -45.39% |
| Income Tax Expenses | 105.59% | 155.20% | -20.29% | -336.50% | -254.30% |
| Earnings from Continuing Operations | -78.19% | 286.62% | -6.14% | -108.57% | -15.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.20% | 1.18% | -308.49% | -970.86% | -51.99% |
| Net Income | -78.22% | 286.26% | -6.18% | -108.64% | -15.23% |
| EBIT | -91.63% | 141.82% | -4.00% | -66.66% | -54.54% |
| EBITDA | -27.32% | 50.77% | -2.67% | -38.86% | -24.20% |
| EPS Basic | -78.45% | 284.09% | -7.04% | -108.59% | -15.99% |
| Normalized Basic EPS | -222.14% | 271.91% | -0.74% | -73.89% | -76.79% |
| EPS Diluted | -78.45% | 281.08% | -7.59% | -108.59% | -15.15% |
| Normalized Diluted EPS | -222.14% | 265.73% | -1.32% | -73.89% | -76.55% |
| Average Basic Shares Outstanding | 1.04% | 1.17% | 0.93% | 0.87% | 0.91% |
| Average Diluted Shares Outstanding | 1.04% | 2.88% | 1.53% | 0.87% | -0.11% |
| Dividend Per Share | -- | 1.32% | -- | -6.92% | -- |
| Payout Ratio | 3.68% | 1.53% | -0.01% | -10.04% | 0.21% |
